Related Experiment Video
Updated: Sep 5, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder
1Department of Medical, Surgical Sciences, University "Magna Græcia" of Catanzaro, Neurology Unit, Italy.
Abstract:
Satralizumab, an antibody against IL-6R, has been recently approved in Neuromyelitis optica spectrum disorder(NMOSD). Targeting IL-6 or IL-6 Receptor(like Satralizumab does) results in inhibition of both pro and anti-inflammatory pathways of IL-6. Sgp130FC(Olamkicept) is a monoclonal antibody that prevents only the proinflammatory pathway of IL-6 to be activated, and could represent a better way to target IL-6 pathway in Neuromyelitis optica spectrum disorder.
More Related Videos
12:23Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
08:03Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014